This policy document targets the procurement and management of medical gases, and focuses on nitrous oxide (N2O) and 50% nitrous oxide and 50% oxygen mix commonly known under the tradename Entonox®.
This project aims to stop all use of the anaesthetic gas desflurane in hospitals in Wales. This is because of its excessive environmental impact, lack of clinical benefit when compared to more recently available alternatives, and high cost.
This document sets out a national strategy to reduce the carbon footprint of inhalers in Wales, and outlines the key actions for the NHS and its partners in Wales to:
This strategy sets out the steps the NHS and its partners in Wales will take to support the conditions needed to create a strong, competitive biological and biosimilar medicines’ market in the UK benefiting the NHS, patients and the economy of Wales.